HCMN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow reported leverage provides durable financial flexibility: it supports continued R&D and commercialization investment, offers a cushion against clinical or commercial setbacks, and reduces likelihood of immediate debt-driven distress that could force asset sales or rushed partnerships.
Diversified Revenue ModelA business model combining commercial product sales with collaboration and licensing income creates multiple cash avenues: product revenue, milestone and royalty streams, and cost-reimbursement structures. This diversification reduces single-market dependency and supports funding development over the medium term.
Commercial-stage Products With Reasonable MarginsSustained gross margins near 39% and having marketed products indicate established unit economics and commercialization capability. Those attributes enable scalability once sales growth resumes and make future margin recovery or incremental product launches more likely to contribute to durable profitability.
Bears Say
Revenue DeclineA material revenue drop and choppy top-line trajectory undermine predictability of future cash flows and the payback profile for R&D and commercial investments. Persistent or repeated declines risk eroding market share and make long-term planning and resource allocation more difficult for management.
Operating Profitability DeteriorationTurning from operating profit to operating loss indicates weaker core business economics; it reduces the company's ability to self-fund development and commercialization. Sustained operating losses increase reliance on external funding or partner deals, raising execution and dilution risks over months.
Weak Cash GenerationNegative operating and free cash flow despite a strong balance sheet implies the business is consuming cash to operate. Over a multi-month horizon this can force financing, slow programs, or require milestones/partner funding. Reported net income not backed by cash raises earnings-quality concerns.
HUTCHMED News
HCMN FAQ
What was HUTCHMED’s price range in the past 12 months?
Currently, no data Available
What is HUTCHMED’s market cap?
HUTCHMED’s market cap is $34.27B.
When is HUTCHMED’s upcoming earnings report date?
HUTCHMED’s upcoming earnings report date is Jul 30, 2026 which is tomorrow.
How were HUTCHMED’s earnings last quarter?
HUTCHMED released its earnings results on Mar 05, 2026. The company reported $0.174 earnings per share for the quarter, missing the consensus estimate of $43.608 by -$43.434.
Is HUTCHMED overvalued?
According to Wall Street analysts HUTCHMED’s price is currently Undervalued.
Does HUTCHMED pay dividends?
HUTCHMED does not currently pay dividends.
What is HUTCHMED’s EPS estimate?
HUTCHMED’s EPS estimate is 2.53.
How many shares outstanding does HUTCHMED have?
HUTCHMED has 174,467,030 shares outstanding.
What happened to HUTCHMED’s price movement after its last earnings report?
HUTCHMED reported an EPS of $0.174 in its last earnings report, missing expectations of $43.608. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of HUTCHMED?
Currently, no hedge funds are holding shares in MX:HCMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HUTCHMED Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$259.32 (― Upside)
$259.32 (― Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.97%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
37.59%
Trailing 12-Months
Company Description
HUTCHMED
HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Its operations are divided into two main areas: Oncology/Immunology and a segment encompassing Other Ventures. The company's reach extends from Hong Kong globally. Among its pipeline, HUTCHMED is developing Savolitinib, an inhibitor targeting non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Another key therapeutic, Fruquintinib, is an inhibitor being investigated for its efficacy in CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and a range of other gastrointestinal and solid tumors. Furthermore, the company's portfolio includes Surufatinib, an inhibitor applicable to numerous conditions such as neuroendocrine tumors (NETs - both pancreatic and non-pancreatic), biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, gastric cancer (GC), thyroid cancer, endometrial cancer (EMC), NSCLC, and general solid tumors. HMPL-523, a spleen tyrosine kinase inhibitor, is designed to treat hematological cancers and specific chronic immune conditions, while HMPL-689 targets the isoform PI3Kd (phosphoinositide 3'-kinase delta). Additional compounds in development include Tazemetostat, an EZH2 inhibitor indicated for specific epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor showing promise for hematological malignancies, gliomas, and solid tumors; HMPL-760, which functions as a Bruton's tyrosine kinase inhibitor; and HMPL-453, an inhibitor aimed at intrahepatic cholangiocarcinoma. The pipeline also features HMPL-295 for solid tumors, HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors, alongside Epitinib (HMPL-813) and Theliatinib (HMPL-309), both of which act as inhibitors. HUTCHMED maintains strategic collaboration agreements with a number of partners, including AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The entity, established in 2000 and headquartered in Central, Hong Kong, was previously identified as Hutchison China MediTech Limited before officially adopting its current name, HUTCHMED (China) Limited, in May 2021.
HCMN Company Deck
HCMN Earnings Call
Q4 2026
0:00 / 0:00